

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 4

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 - 43 (Canceled)

44. (New) An attenuated *Salmonella* sp. which expresses an F' pilus and produces a filamentous bacteriophage, whereby said *Salmonella* strain is non-pyrogenic and tumor-targeting.
45. (New) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. is *Salmonella enteritidis*.
46. (New) The *Salmonella* sp. of claim 45, wherein the *Salmonella enteritidis* is *Salmonella typhimurium*.
47. (New) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. is attenuated by a mutation selected from the group consisting of a lipid mutation, a *pux*⁻ mutation, and a combination thereof.
48. (New) The *Salmonella* sp. of claim 47, wherein the lipid mutation is *msbB*⁻.
49. (New) The *Salmonella* sp. of claim 46, wherein the *Salmonella typhimurium* is derived from the strain selected from the group consisting of YS72 (ATCC Accession No. 55680), YS1456 (ATCC Accession No. 202164), and YS1646 (ATCC Accession No. 202165).

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 5

50. (New) The *Salmonella* sp. of claim 44, wherein the filamentous bacteriophage is selected from the group consisting of pBSKIIIGFP, M13KO7, and pSKAN8.
51. (New) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. produces the bacteriophage directly within tumors.
52. (New) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. delivers at least 1.7×10^9 p.f.u. (plaque forming unit) of bacteriophage/gram of tumor.
53. (New) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. delivers about 5.9×10^9 p.f.u. (plaque forming unit) of bacteriophage/gram of tumor.
54. (New) The *Salmonella* sp. of claim 44, wherein the bacteriophage expresses a proteinaceous molecule.
55. (New) The *Salmonella* sp. of claim 54, wherein the proteinaceous molecule is selected from the group consisting of green fluorescent protein (GFP), IL-2/pIII fusion protein, and listeriolysin O 91-99.
56. (New) The *Salmonella* sp. of claim 44, wherein the bacteriophage possesses a eukaryotic promoter.
57. (New) The *Salmonella* sp. of claim 56, wherein the eukaryotic promoter is a CMV promoter.

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 6

58. (New) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. is lac⁺ and kanamycin-resistant.
59. (New) The *Salmonella* sp. of claim 49, wherein the *Salmonella typhimurium* is the strain selected from the group consisting of 72-F'-M13K07 and msbB⁻8.7-F'-M13K07.
60. (New) A composition comprising the *Salmonella* sp. of claim 44 and a pharmaceutically-acceptable carrier.
61. (New) A method of delivering a bacteriophage to a solid tumor, comprising the intravenous administration of an attenuated tumor-targeting *Salmonella* sp. which expresses an F' pilus and produces a filamentous bacteriophage, whereby said *Salmonella* strain is non-pyrogenic and tumor-targeting.
62. (New) A kit comprising an attenuated *Salmonella* sp. which expresses an F' pilus and produces a filamentous bacteriophage, whereby said *Salmonella* strain is non-pyrogenic and tumor-targeting.